Table 1.
Pooled baseline demographics, clinical characteristics, and treatment history of patients treated with secukinumab 300 mg (n = 691)a
| Age, years | 44.9 (13.3) |
| Male, n (%) | 477 (69.0) |
| Body weight, kg | 86.6 (23.2) |
| Body mass index, kg/m2 | 29.4 (6.9) |
| Race, n (%) | |
| White | 505 (73.1) |
| Asian | 129 (18.7) |
| Native American | 29 (4.2) |
| Black | 9 (1.3) |
| Pacific Islander | 4 (0.6) |
| Other | 13 (1.9) |
| Unknown | 2 (0.3) |
| IGA score, n (%) | |
| 0 = clear | 0 |
| 1 = almost clear | 0 |
| 2 = mild | 0 |
| 3 = moderate | 436 (63.1) |
| 4 = severe | 255 (36.9) |
| BSA, % involvement (n = 690) | 33.0 (18.8) |
| PASI score | 22.7 (9.4) |
| DLQI score (n = 676) | 13.5 (7.3) |
| Severity of psoriasis, n (%) | |
| Moderate | 202 (29.2) |
| Severe | 489 (70.8) |
| Time since first diagnosis of psoriasis, years | 17.0 (12.0) |
| Psoriatic arthritis present, n (%) | 126 (18.2) |
| Time since first diagnosis of psoriatic arthritis, years | 8.1 (8.3) |
| Previous exposure to psoriasis therapy, n (%) | |
| Systemic therapy | 438 (63.4) |
| Biologic systemic therapy | 146 (21.1) |
| Nonbiologic systemic therapy | 373 (54.0) |
All values were calculated on the basis of available data and are presented as means (SD) unless otherwise stated. BSA, body surface area; DLQI, Dermatology Life Quality Index; IGA, 5-point Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.
a
Patients with moderate-to-severe psoriasis randomized to secukinumab 300 mg in the ERASURE, FIXTURE, FEATURE, and JUNCTURE clinical trials.